{"id":"neostigmine-w-glycopyrrolate","safety":{"commonSideEffects":[{"rate":null,"effect":"Salivation"},{"rate":null,"effect":"Bronchospasm"},{"rate":null,"effect":"Bradycardia"},{"rate":null,"effect":"Muscle fasciculations"},{"rate":null,"effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL278020","moleculeType":"Small molecule","molecularWeight":"223.30"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Neostigmine is a reversible acetylcholinesterase inhibitor that increases acetylcholine concentration at the neuromuscular junction and in the central and peripheral nervous systems. Glycopyrrolate is an anticholinergic agent added to this combination to prevent excessive muscarinic stimulation (salivation, bronchospasm, bradycardia) that would otherwise result from neostigmine monotherapy. Together, they enhance nicotinic effects while minimizing unwanted muscarinic effects.","oneSentence":"Neostigmine inhibits acetylcholinesterase to increase acetylcholine levels, while glycopyrrolate blocks muscarinic receptors to counteract cholinergic side effects.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:38:32.556Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Myasthenia gravis"},{"name":"Reversal of neuromuscular blockade"}]},"trialDetails":[{"nctId":"NCT03168308","phase":"PHASE4","title":"Sugammadex vs. Neostigmine for Neuromuscular Blockade Reversal in Thoracic Surgical Patients","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2017-09-26","conditions":"Neuromuscular Blockade","enrollment":92}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Neostigmine w/ Glycopyrrolate","genericName":"Neostigmine w/ Glycopyrrolate","companyName":"University of Texas Southwestern Medical Center","companyId":"university-of-texas-southwestern-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Neostigmine inhibits acetylcholinesterase to increase acetylcholine levels, while glycopyrrolate blocks muscarinic receptors to counteract cholinergic side effects. Used for Myasthenia gravis, Reversal of neuromuscular blockade.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}